Lung cancer: open trials in Switzerland

65 open trials have a site in Switzerland. Registry data; only the trial team decides who can take part.

NCT05384626
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Trial Treatment · Phase 1/2 · Nuvalent Inc.
Istituto Oncologico Svizzera Italiana, Bellinzona · Luzerner Kantonsspital, Lucerne
Registry updated 2026-11-06
NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Kantonsspital Aarau, Aarau · Kantonsspital Baden, Baden · Universitaetsspital Basel, Basel · Universitaetsspital Zuerich, Zurich
Registry updated 2026-11-06
NCT06284317
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Trial Treatment · Phase 3 · ETOP IBCSG Partners Foundation
Kantonsspital Baden, Baden · Universitätsspital Basel, Basel · Eoc - Iosi, Bellinzona · Inselspital Bern, Bern · HFR Hôpital Fribourgeois, Fribourg · CHUV, Lausanne · Kantonsspital St. Gallen, Sankt Gallen · Kantonsspital Winterthur, Winterthur · University Hospital Zurich, Zurich
Registry updated 2026-11-06
NCT06881784
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Trial Treatment · Phase 3 · Revolution Medicines, Inc.
Universitätsspital Basel, Basel · HFR Fribourg/Kantonsspital Fribourg, Fribourg · HOCH Health Ostschweiz - Kantonsspital St. Gallen, Sankt Gallen · Kantonsspital St. Gallen, Sankt Gallen
Registry updated 2026-11-06
NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Universitätsspital Basel, Basel · Inselspital Bern, Bern
Registry updated 2026-11-05
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Hoffmann-La Roche
Kantonsspital Baden, Baden · Universitaetsspital Basel, Basel · Kantonsspital Graubünden Medizin Onkologie, Chur · Hôpital Universitaire de Genève (HUG), Geneva
Registry updated 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Universitaetsspital Basel, Basel · Ospedale Regionale Bellinzona e Valli, Bellinzona · Kantonsspital Münsterlingen - Spital Thurgau AG, Münsterlingen · Kantonsspital St. Gallen, Sankt Gallen
Registry updated 2026-11-05
NCT07563738
A 2-part Phase 1/2 Open-label Trial on ODM-212
Trial Treatment · Phase 1/2 · Orion Corporation, Orion Pharma
Ospedale Regionale Bellinzona, Bellinzona
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
CHUV (centre hospitalier universitaire vaudois), Lausanne · Kantonsspital Winterthur, Winterthur
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Kantonsspital Baden, Baden · HFR Freiburg-Kantonsspital, Fribourg
Registry updated 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Kantonsspital Baden, Baden · HFR Fribourg - Hôpital cantonal, Fribourg · Kouros Moccia Oncologia, Locarno
Registry updated 2026-11-04
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Trial Treatment · Phase 2/3 · BioNTech SE
Kantonspital Baden, Baden · Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) - Centre de transplantation d'organes (CTO), Lausanne · Kantonsspital Münsterlingen, Münsterlingen
Registry updated 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Local Institution - 007-397, Sankt Gallen · Local Institution - 007-396, Villars-sur-Glâne
Registry updated 2026-10-30
NCT06931717
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Trial Treatment · Phase 3 · ETOP IBCSG Partners Foundation
University Hospital Basel, Basel · Kantonsspital Winterthur, Winterthur
Registry updated 2026-10-28
NCT07020065
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Trial Treatment · Phase 2 · Swiss Cancer Institute
Kantonsspital Aarau, Aarau · Kantonsspital Baden, Baden · Universitätsspital Basel, Basel · EOC Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona · Inselspital, Bern · TUCARE Bülach AG, Bülach · Kantonsspital Graubuenden, Chur · Spital Thurgau AG - Kantonsspital Frauenfeld, Frauenfeld · HFR Fribourg, Fribourg · Hôpitaux universitaires de Genève, Geneva · Kantonsspital Baselland, Liestal · Kantonsspital Olten - Solothurner Spitäler, Olten · HOCH Health Ostschweiz - Kantonsspital St. Gallen, Sankt Gallen · Spital Limmattal, Schlieren · Hôpital du Valais - Sion, Sion · Spital STS AG, Thun · Kantonsspital Winterthur, Winterthur · Stadtspital Zürich Triemli, Zurich
Registry updated 2026-10-28
NCT07149649
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 2/3 · Swiss Cancer Institute
Tumorzentrum Aarau - Hirslanden TZA, Aarau · Kantonsspital Baden, Baden · St. Claraspital, Basel · Universitätsspital Basel, Basel · Kantonsspital Graubuenden, Chur · Luzerner Kantonsspital, Lucerne · Kantonsspital Olten, Olten · HOCH Health Ostschweiz - Kantonsspital St. Gallen, Sankt Gallen · Kantonsspital Winterthur, Winterthur
Registry updated 2026-10-28
NCT07158489
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
Trial Treatment · Phase 2 · Swiss Cancer Institute
Kantonsspital Baden, Baden · Universitätsspital Basel, Basel · Kantonsspital Graubuenden, Chur · Hôpital Fribourgeois - Hôpital Cantonal, Fribourg · Hôpitaux universitaires de Genève, Geneva · HOCH Health Ostschweiz - Kantonsspital St. Gallen, Sankt Gallen · Spital STS AG, Thun · Kantonsspital Winterthur, Winterthur
Registry updated 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
Kantonsspital Baden AG, Baden · Centre Hospitalier Universitaire Vaudois, Lausanne
Registry updated 2026-10-28
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Trial Treatment · Phase 3 · Mirati Therapeutics Inc.
Kantonsspital Münsterlingen - Spital Thurgau AG, Münsterlingen
Registry updated 2026-10-27
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Klinik fur Hamatologie und Onkologie Hirslanden Zurich (Site 4001), Zurich · Stadtspital Zürich Triemli - Klinik für Medizinische Onkologie und Hämatologie (Site 4000), Zurich
Registry updated 2026-10-26
NCT07246863
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Trial Treatment · Phase 2 · CatalYm GmbH
University Hospital Basel, Basel · Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology, Sankt Gallen
Registry updated 2026-10-26
NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Basel · Bellinzona · Lausanne · Münsterlingen
Registry updated 2026-10-23
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Centre Hospitalier Universitaire Vaudois, Lausanne · Sankt Gallen · Onkologiezentrum Thun-Berner Oberland Spital Sts Ag, Thun · Villars-sur-Glâne
Registry updated 2026-10-23
NCT07699861
LUCINAE Registry: Thoracic Cancers During Pregnancy
Research · Oncology Institute of Southern Switzerland
Kantonsspital Baden, Baden · Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona · Geneva University Hospital (HUG), Geneva · Kantonsspital Winterthur, Winterthur
Registry updated 2026-10-21
NCT07860359
Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers
Trial Treatment · Hôpital Fribourgeois
Fribourg Cantonal Hospital (HFR), Fribourg
Registry updated 2026-10-21

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error